Last: | |||
Change: | Change(%): | ||
Volume: | Open: | ||
High: | Low: | ||
52Wk High: | 52Wk Low: |
Assembly Biosciences is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients.